Rmpl Pharma LLP

RMPL Pharma LLP, established on May 16, 2015, is a Mumbai-based pharmaceutical exporter specializing in oncology and specialized products. As a part of the Royal Group of companies, which dates back to 1944, RMPL Pharma has built a reputation as a leading merchant exporter in India. The company is registered under the Corporate Identification Number (CIN) AAD-9570. While specific revenue figures are not publicly disclosed, RMPL Pharma operates with a total obligation of contribution of ₹98,000. The firm employs a dedicated team of 23 professionals, including designated partners Mahendra Mukundlal Gandhi and Asan Mohideen Nagoormeeran Sheik Packeer. Their official website is www.rmplpharma.com.

RMPL Pharma LLP operates from its headquarters located at Office No. S-1, Ground Floor, Sharda Chambers Premises Co-Operative Society Limited, New Marine Lines, Churchgate, Mumbai, Maharashtra, India. The company specializes in the export and wholesale distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details about manufacturing plant locations and capacities are not publicly disclosed, RMPL Pharma sources its products from reputed Indian and multinational manufacturers, ensuring adherence to international quality standards.

The leadership team at RMPL Pharma LLP comprises:

• Mahendra Mukundlal Gandhi: Designated Partner since May 16, 2015.

• Asan Mohideen Nagoormeeran Sheik Packeer: Designated Partner since May 16, 2015.

These leaders bring extensive experience to the company, driving its strategic direction and operational excellence.

RMPL Pharma LLP has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports a diverse range of pharmaceutical products, primarily focusing on oncology and specialized medications. While specific regulatory filings and approvals are not publicly disclosed, RMPL Pharma's adherence to international quality standards, as evidenced by certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, underscores its commitment to meeting the stringent requirements of these markets.

RMPL Pharma LLP has expanded its reach to emerging markets across Africa, Latin America, and Southeast Asia. The company's export activities span over 25 countries, including Saudi Arabia, Yemen, Turkey, Syria, Lebanon, Kenya, Uganda, Hong Kong, Egypt, Libya, Sri Lanka, Tanzania, Djibouti, Ghana, Iran, Jordan, Thailand, Dubai, Somaliland, and Iraq. While specific details about WHO prequalification are not publicly available, RMPL Pharma's adherence to international quality standards, as evidenced by certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, suggests a commitment to meeting the requirements for access to these markets.

RMPL Pharma LLP demonstrates a diversified geographic strategy by exporting to over 25 countries across Africa, the Middle East, Europe, and Southeast Asia. This broad market presence mitigates concentration risk and positions the company to leverage growth opportunities in various regions. The strategic focus on oncology and specialized products aligns with global healthcare needs, enhancing the company's competitive edge in these markets.

Specific details regarding RMPL Pharma LLP's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the company's adherence to international quality standards, as evidenced by certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, indicates a commitment to meeting the stringent requirements of regulated markets, including the United States.

RMPL Pharma LLP holds certifications that reflect its commitment to quality and compliance with international standards:

• WHO-GMP Certification: Indicates adherence to the World Health Organization's Good Manufacturing Practices, ensuring the quality of pharmaceutical products and good distribution and trading practices.

• ISO 9001:2015 Certification: Demonstrates the company's ability to meet international standards, bringing standardized practices to organizational and administrative work.

• ISO 45001:2018 Certification: Specifies requirements for an occupational health and safety management system, enabling organizations to provide safe and healthy workplaces.

While specific details about EU GMP certificates and EDQM status are not publicly available, RMPL Pharma's adherence to these certifications suggests a commitment to meeting the requirements of the European Union market.

Specific details regarding RMPL Pharma LLP's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. However, the company's adherence to international quality standards, as evidenced by certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, indicates compliance with regulatory requirements.

As of March 28, 2026, there are no publicly available records of FDA Form 483 observations, warning letters, or import alerts associated with RMPL Pharma LLP. The company's adherence to international quality standards, as evidenced by certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, suggests a proactive approach to regulatory compliance.

In the oncology and specialized pharmaceutical export sector, RMPL Pharma LLP faces competition from both Indian and multinational companies. While specific market share data is not publicly available, RMPL Pharma's focus on high-quality products, adherence to international standards, and broad geographic reach position it competitively in the market. The company's commitment to ethical business practices and financial discipline further enhances its standing among competitors.

RMPL Pharma LLP distinguishes itself through several key factors:

• Extensive Product Range: Offering over 6,000 marketed products, including original brands and true generics, primarily in oncology and specialized therapeutic areas.

• International Certifications: Holding certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, demonstrating adherence to global quality standards.

• Global Reach: Exporting to over 25 countries across Africa, the Middle East, Europe, and Southeast Asia, showcasing a diversified geographic strategy.

RMPL Pharma LLP's current strategic direction focuses on exporting a diverse range of finished pharmaceutical formulations, with a strong emphasis on oncology and specialized products. The company's adherence to international quality standards and its broad geographic reach position it well for future growth. While specific plans regarding generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services are not publicly disclosed, RMPL Pharma's commitment to quality and ethical business practices suggests a proactive approach to evolving market demands.

RMPL Pharma LLP demonstrates a strong track record in the pharmaceutical export sector, with a total export value of $439,000 USD and 326 shipments across 13 products in three therapeutic categories. The company's portfolio concentration is notable, with the top five products accounting for 82.1% of exports. This concentration indicates a focused approach to product offerings. The company's adherence to international quality standards, as evidenced by certifications such as WHO-GMP, ISO 9001:2015, and ISO 45001:2018, underscores its reliability as a supplier.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• WHO-GMP Certification: Indicates adherence to the